Spano, Jean-Philippe

Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study

Salem, J.-E., Manouchehri, A., Moey, M., Lebrun-Vignes, B., Bastarache, L., Pariente, A., Gobert, A., Spano, J.-P., Balko, J. M., Bonaca, M. P., et al. (2018) · The Lancet Oncology

Cancer Immunotherapy and BiomarkersPharmacovigilance and Adverse Drug Reactions

Cited by 1,271

Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy

Sistigu, A., Yamazaki, T., Vacchelli, E., Chaba, K., Enot, D. P., Adam, J., Vitale, I., Goubar, A., Baracco, E. E., Remédios, C., et al. (2014) · Nature Medicine

interferon and immune responsesImmunotherapy and Immune Responses

Cited by 1,042

Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade—a worldwide perspective

Gougis, P., Jochum, F., Abbar, B., Dumas, E., Bihan, K., Lebrun-Vignes, B., Moslehi, J., Spano, J.-P., Laas, E., Hotton, J., et al. (2024) · eClinicalMedicine

Cancer Immunotherapy and BiomarkersPharmacovigilance and Adverse Drug Reactions

Cited by 161

Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients with Advanced Cancer with RAS–RAF Mutations

Zimmer, L., Barlesi, F., Martinez-Garcia, M., Dieras, V., Schellens, J. H. M., Spano, J.-P., Middleton, M. R., Calvo, E., Paz-Ares, L., Larkin, J., et al. (2014) · Clinical Cancer Research

Melanoma and MAPK PathwaysProtein Tyrosine Phosphatases

Cited by 71

Patients' preference of trastuzumab administration (subcutaneous versus intravenous) in HER2-positive metastatic breast cancer: Results of the randomised MetaspHer study

Pivot, X., Spano, J. P., Espie, M., Cottu, P., Jouannaud, C., Pottier, V., Moreau, L., Extra, J. M., Lortholary, A., Rivera, P., et al. (2017) · European Journal of Cancer

HER2/EGFR in Cancer ResearchHealth Systems, Economic Evaluations, Quality of Life

Cited by 70